A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have shared their insights on Harmony Biosciences (NASDAQ:HRMY), with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $49.71, slightly down from the previous $50.00. Analysts have maintained or raised their ratings, reflecting positive sentiment. Harmony Biosciences has shown strong revenue growth and profitability but faces challenges in return on equity.
June 21, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has received mostly bullish ratings from analysts, with an average 12-month price target of $49.71. The company has shown strong revenue growth and profitability, though it faces challenges in return on equity.
The majority of analysts have given bullish ratings, and the average price target is close to the current price, indicating positive sentiment. The company's strong revenue growth and profitability further support a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100